发明授权
US07371577B2 FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
失效
哺乳动物细胞中FLP介导的基因修饰,以及对其有用的组合物和细胞
- 专利标题: FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
- 专利标题(中): 哺乳动物细胞中FLP介导的基因修饰,以及对其有用的组合物和细胞
-
申请号: US11184156申请日: 2005-07-18
-
公开(公告)号: US07371577B2公开(公告)日: 2008-05-13
- 发明人: Geoffrey M. Wahl , Stephen V. O'Gorman
- 申请人: Geoffrey M. Wahl , Stephen V. O'Gorman
- 申请人地址: US CA La Jolla
- 专利权人: The Salk Institute for Biological Studies
- 当前专利权人: The Salk Institute for Biological Studies
- 当前专利权人地址: US CA La Jolla
- 代理机构: Foley & Lardner LLP
- 代理商 Stephen E. Reiter
- 主分类号: C12N15/87
- IPC分类号: C12N15/87 ; C12N5/00 ; C12N5/02
摘要:
A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent β-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebrate development. The FLP recombination system of the present invention can be incorporated in transgenic, non-human mammals to achieve site-specific integration of transgenes, to construct functional genes or to disrupt existing genes.
公开/授权文献
信息查询
IPC分类: